Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of marstacimab prophylaxis in severe hemophilia A or B with or without inhibitors
CTR20230369Phase 3Active
- Sponsor
- ---/ 辉瑞投资有限公司
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of marstacimab in hemophilia A, hemophilia B (HB), sponsored by ---/ 辉瑞投资有限公司. Started Mar 2023; status: active.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on CTR20230369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230369.